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Abstract: This study aimed to investigate the correlation of adrenal magnetic 
resonance imaging (MRI) mass size and 1 mg dexamethasone suppression test 
results in patients with adrenal incidentaloma diagnosis. Eighty-six patients (82.6% 
female) with incidentally discovered adrenal masses, diagnosed and treated in the 
Department of Endocrinology Bakirkoy Dr. Sadi Konuk Education and Research 
Hospital between June and August 2017, were included in the analysis. All the 
patients evaluated for their hormonal functionality. 24-h urinary excretion of cortisol 
did not correlate with tumor size. But there was a positive correlation between longer 
adrenal nodule diameter and metanephrine, and there was a negative correlation 
between shorter adrenal nodule diameter and renin levels. We found that smaller 
and clinically “silent” tumors often do not demonstrate subclinical hormonal activity.  
Keywords: adrenal incidentaloma; adrenal magnetic resonance imaging mass size; 
metanephrine, renin. 
 
INTRODUCTION  
An incidentaloma is a mass in one or both adrenal glands detected 
accidentally during an imaging study performed for other reasons. The rapid 
development of modern imaging techniques has led to an increase in incidentaloma 
diagnosis without clinically apparent hormonal abnormalities (Babińska et al., 2012; 
Kim et al., 2013; Ekinci et al., 2016). In different studies, the incidence of 
incidentalomas differs between 1.4% and 8% (Ekinci et al., 2016).  
By definition, patients with incidentalomas do not display any physical sign of 
adrenal hormonal excess; because no clinical suspicion has led to the detection of 
the adrenal masses. However, although incidentalomas considered hormonally 
inactive, a.k.a nonfunctional, they have often been associated with a high prevalence 
of hypertension, dyslipidemia, glucose intolerance, and obesity (Muscogiuri et al., 
2011).  
It has shown that these incidental adenomas may secrete small quantities of 
cortisol, and 5-30% of patients with adenomas may have subclinical hypercortisolism 
(Olsen et al., 2014).  
Incidentalomas are a common reason for referral to the endocrine clinics. A 
series of investigations are usually recommended to exclude catecholamine, cortisol, 
or aldosterone oversecretion (Theodoraki et al., 2011). The researches show that 
most of the incidentalomas are nonfunctional and benign adenomas (Ekinci et al.,   
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2016). Recently, many studies have been carried out to determine the characteristics 
of adrenal incidentalomas (Kim et al., 2013, Debono et al., 2014, Libe et al., 2002, 
Erbil and Barbaros, 2008, Kilinc et al., 2015, Kutbay et al., 2015).  
This retrospective observational study aimed to perform an analysis of the 
correlation of adrenal magnetic resonance imaging (MRI) mass size and hormonal 
status (incl. 1 mg dexamethasone suppression test) in patients with adrenal 
incidentaloma. 
 
MATERIALS AND METHOD  
This retrospective cross-sectional study was carried out in Bakirkoy Dr. Sadi 
Konuk Education and Research Hospital after receiving ethical approval from the 
Ethical Review Board of the same institution. A total of 86 patients with adrenal 
masses discovered incidentally on MRI recruited from June to August 2017.  
The age, patient’s gender, MRI based mass size, dexamethasone 
suppression test result, serum levels of morning basal cortisol, free triiodothyronine 
(fT3), free thyroxine (fT4), thyroid-stimulating hormone (TSH), prolactin, 
adrenocorticotropic hormone (ACTH), haemoglobin A1c (HbA1c), fasting blood 
glucose, homeostatic model of assessment insulin resistance (HOMA-IR), renin, 
aldosterone, plasma renin activity, 25-hydroxy vitamin D, dehydroepiandrosterone-
sulfate (DHEA-S), progesterone, 24h urine levels of cortisol, vanillylmandelic acid 
(VMA), metanephrine, normetanephrine, epinephrine, norepinephrine taken from 
patient medical records.  
All venous blood samples draw between 08:00, and 10:00 am. after 12-h 
fasting. In our hospital, the overnight dexamethasone suppression test is performed 
by administering low-dose (1 mg, p.o.) dexamethasone at 11 pm the night before. 
Blood samples for determination of plasma cortisol obtained at 8 am the following 
morning.  
In our hospital, patients instructed on how to collect a 12-hour overnight urine 
sample. The patients give detailed instructions to void at the start time and collect all 
urine until the stop time, at which they completed their last void. Patients transfer 
each voided urine sample to a collection bottle containing a preservative (sodium 
meta bisulfate; NA2S205, crystal form; reagent ACS grade, Fisher Scientific no. 
S244).  
Paramagnetic particle chemiluminescence method at UniCel DxI800 
Immunoassay analyzer (Beckman Coulter Inc, Brea, CA, USA) was used to measure 
the serum level of 25-hydroxy vitamin D. HbA1c was studied with Premier Hb9210-
Primus ultra II device using HPLC (high-performance liquid chromatography) 
method. Urine concentrations of vanillylmandelic acid (VMA), metanephrine, 
normetanephrine, epinephrine, and norepinephrine were quantified by liquid 
chromatography with electrochemical detection. The rest of the biochemical and 
hormonal parameters were measured using Cobas c501 (Roche Diagnostic, USA), 
C6000 autoanalyzer (Roche Diagnostic, USA), Immulite 2000 model analyzer using 
original kits (Siemens Healthcare GmbH, Henkestr, Erlangen, Germany).  
The Homeostatic Model Assessment (HOMA) was used to quantify the Insulin 
Resistance (IR). The approximating equation for IR used a fasting plasma sample 
and derived by the use of the insulin-glucose product divided by a constant: HOMA-
IR = (Glucose (mg/dL) x Insulin) / 405. 
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Statistical Analysis  
Test of normality performed for each variable and Kolmogorov-Smirnov and 
Shapiro-Wilk tests shown. Since the variables did not have a normal distribution, 
nonparametric tests preferred for the analyses. To determine the correlation between 
two data, nonparametric Kendall’s Tau-B correlation test used. For testing group 
differences, Mann-Whitney U for two groups was carried out. Due to the lack of 
normal distribution, the median and range give for continuous data. Frequency 
distribution tables interpreted for categorical data. Analyses were carried out with 
SPSS 22.0 version significance level was p<0.05. 
 
RESULTS AND DISCUSSION  
Out of 86 patients,17.4% (15 patients) were male and 82.6% (71 patients) 
were female. The median age was 48.5; where the minimum age was 14 years, and 
the maximum was 90 years. Of these patients, 58.1% (50 patients) had a nodule in 
the right adrenal lobe, while 65.1% (56 patients) had a nodule on the left adrenal 
lobe. 23.3% (20) had nodules in both adrenal lobes (Table 1).  
According to incidentaloma size, the median longer nodule diameter was 21  
mm while the median shorter nodule diameter was 15 mm. Median basal cortisol 
level was 14.17 μg/dl. The median cortisol level after 1 mg dexamethasone 
suppression test was 1.26 nmol/l, with a minimum level of 0.21 nmol/l and a 
maximum level of 10.88 nmol/l.  
Median metanephrine in urine was 56.8 μg/24h, while the minimum level was 
2.34 μg/24h, and the maximum level was 143.26 μg/24h. The median renin level 
was 55.65 pg/mL, with minimum and maximum levels of 21.4 pg/mL and 97 pg/mL, 
respectively. Median insulin resistance was 3.3 mg/dl, where the minimum and 
maximum levels were 1.4 mg/dl and 8.9 mg/dl, respectively.  
Median, distribution range, minimum, and maximum values of the variables of 
86 patients with adrenal incidentaloma shown in Table 2. The relationship between 
adrenal mass size and 1 mg dexamethasone suppression test results was not 
statistically significant (see table 3 for p values).  
Shorter nodule diameter was statistically significant according to gender. As 
for mean rank values of the two nodule diameters, they are more significant in 
females and smaller in males. Other variables were not statistically significant (see 
table 5 for p values). Longer adrenal nodule diameter was significantly correlated 
only with metanephrine (p = 0.001, Table 4). Shorter adrenal nodule diameter is 
significantly correlated only with renin (p = 0.02, Table 6). 
 
Table 1. Distribution of Incidentaloma Nodules  
 
 Site No (%) 
 Right lobe 58.1% (50) 
 Left lobe 65.1% (56) 
 Both lobes 23.3% (20) 
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Table 2. Variables of 86 Patients with Adrenal Incidentaloma  
 
Variables Median Range Minimum Maximum 
Age (year) 48.5 76 14 90 
Longer Nodule     
Diameter (mm) 21 74 3 77 
Shorter Nodule     
Diameter (mm) 15 72.5 1.5 74 
Basal Cortisol (Urine)     
(μg/dl) 14.17 36.09 6.78 42.87 
Cortisol After     
Dexamethasone Sup.     
(nmol/l) 1.265 10.67 0.21 10.88 
FT3 (ng/dl) 2.91 2035.22 0.78 2036 
FT4 (μg/dl) 2.35 5.42 1.03 6.45 
TSH (μIU/ml) 4.585 45.37 0.43 45.8 
Prolactin (μg/l) 12.66 41.1 4.5 45.6 
ACTH (pg/ml) 16.7 62 5 67 
HbA1c (%) 5.95 5.2 3.7 8.9 
FBG (mg/dl) 91.5 80 65 145 
HOMA_IR (mg/dl) 3.3 7.5 1.4 8.9 
Renin (pg/mL) 55.65 75.6 21.4 97 
Aldosterone (ng/dl) 19.75 94.1 3.7 97.8 
Plasma Renin Activity     
(ng/ml/h) 12.85 82.51 0.29 82.8 
25-Hydroxy Vitamin D     
(ng/ml) 23 64 3 67 
DHEA-S (mg/ml) 72.7 212 8.5 220.5 
Progesterone (ng/ml) 2.67 66.8 0.2 67 
Cortisol (Urine) (μg) 90.44 595.8 21.4 617.2 
VMA (Urine) (mg/24 h) 8.965 85.16 3.24 88.4 
Metanephrine (Urine)     
(μg/24 h) 56.8 143.26 2.34 145.6 
Normetanephrine     
(Urine)(μg/24 h) 192.05 610.4 67.8 678.2 
Epinephrine (Urine)     
(ng/l) 5.635 67.6 0.2 67.8 
Norepinephrine (Urine)     
(pg/ml) 46.2 555.7 11.3 567  
FT3: free triiodothyronine; FT4: free thyroxine; TSH: thyroid stimulating hormone; 
ACTH: adrenocorticotropic hormone; HbA1c: haemoglobin A1c; FBG: fasting blood 
glucose; HOMA_IR: homeostatic model of assessment_insulin resistance; DHEA-S: 
dehydroepiandrosterone-sulfate; VMA: vanillylmandelic acid. 
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Table 3. Correlation between adrenal MRI mass size and 1 mg dexametasone 
suppression test (n=86) 
 
   1 mg 
 Correlation  Dexamethason 
Variables Analysis Basal Cortisol Suppression Test 
Longer Nodule Correlation 
.030 .100 
Diameter Coefficient (r)   
 p value 
.684 .178   
Shorter Nodule Correlation 
-.026 .127 
Diameter Coefficient (r)   
 p value 
.725 .091   
    
 
 
Table 4. Correlation Between Longer Adrenal Nodule Diameter and 
Biochemical Parameters 
 
 Correlation  
Variables Coefficient (r) p value 
FT3 -0.03 0.72 
FT4 -0.09 0.21 
TSH -0.13 0.09 
Prolactin 0.10 0.17 
ACTH -0.06 0.40 
HbA1c -0.06 0.42 
FBG 0.11 0.14 
HOMA_IR -0.14 0.07 
Renin -0.09 0.22 
Aldosterone -0.12 0.12 
Plasma Renin Activity 0.05 0.46 
25-Hydroxy Vitamin D 0.01 0.85 
DHEA-S 0.00 0.97 
Progesterone 0.00 0.96 
Cortisol -0.04 0.60 
VMA -0.06 0.44 
Metanephrine 0.23 0.00* 
Normetanephrine 0.07 0.35 
Epinephrine 0.13 0.09 
Norepinephrine 0.14 0.06  
*p<0.05; statistically significant.  
FT3: free triiodothyronine; FT4: free thyroxine; TSH: thyroid stimulating hormone; 
ACTH: adrenocorticotropic hormone; HbA1c: haemoglobin A1c; FBG: fasting blood 
glucose; HOMA_IR: homeostatic model of assessment_insulin resistance; DHEA-S: 
dehydroepiandrosterone-sulfate; VMA: vanillylmandelic acid. 
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Table 5. Correlation Between Adrenal MRI Mass Size and 1 mg Dexametasone 
Suppression Test According to Sex (15 Male, 71 Female; n=86) 
 
  Mean Mann-Whitney  
 Sex Rank U test p value 
Basal Cortisol Male 47.50   
 Female 42.65 472.50 0.494 
Dexa. Sup. T. Male 34.57   
 Female 45.39 398.50 0.127 
Longer Nodule Diameter 
Male 33.33 
  
   
 Female 45.65 380.21 0.092 
Shorter Nodule Diameter Male 29.13   
 Female 46.54 317.93 0.014*  
*p<0.05; statistically significant. 
 
Table 6. Correlation between shorter adrenal nodule diameter and biochemical 
parameters 
 
 Correlation  
Variables Coefficient (r) p value 
FT3 -0.11 0.16 
FT4 0.08 0.32 
TSH -0.08 0.28 
Prolactin 0.14 0.07 
ACTH -0.06 0.39 
HbA1c -0.06 0.40 
FBG -0.05 0.54 
HOMA_IR 0.05 0.51 
Renin -0.17 0.02* 
Aldosterone 0.03 0.66 
Plasma Renin Activity -0.13 0.09 
25-Hydroxy Vitamin D 0.02 0.84 
DHEA-S -0.08 0.27 
Progesterone -0.02 0.76 
Cortisol -0.03 0.73 
VMA 0.04 0.56 
Metanephrine -0.01 0.88 
Normetanephrine 0.08 0.27 
Epinephrine -0.06 0.39 
Norepinephrine 0.05 0.50  
* p<0.05; statistically significant.  
FT3: free triiodothyronine; FT4: free thyroxine; TSH: thyroid stimulating 
hormone; ACTH: adrenocorticotropic hormone; HbA1c: haemoglobin A1c; FBG:  
fasting blood glucose; HOMA_IR: homeostatic model of assessment_insulin 
resistance; DHEA-S: dehydroepiandrosterone-sulfate; VMA: vanillylmandelic 
acid. 
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In the literature, adrenal incidentalomas were more prevalent in middle-aged 
and elderly subjects (Ekinci et al., 2016, Debono et al., 2014, Erbil and Barbaros, 
2008, Comlekci et al., 2009). The previous studies have shown that ischemia and 
atrophy related to aging lead to compensatory hyperplasia in the cortical cells. This 
observation and the increase in the success of radiological procedures can account 
for this higher prevalence in the elderly. Clinically overt hormone hypersecretion 
syndromes were mainly shown in young subjects, while adrenal gland malignancies 
and sCS were more common in older ages (Comlekci et al., 2009).  
In our study, the female/male ratio was 4.7 (71 F/15 M), which is similar to 
another study performed in a Turkish population (Ekinci et al., 2016), whereas higher 
than the ratio found in the literature.  
Since most of the adrenal tumors incidentally discovered, there are no clinical 
signs of adrenal hormonal excess. But, it is still not clear whether an incidentaloma 
puts the patient at an increased risk of harmful outcomes. Literature shows that 
incidentalomas have often been associated with a high prevalence of hypertension, 
dyslipidemia, glucose intolerance, and obesity (Muscogiuri et al., 2011; Turan et al., 
2015). By this, our series had a median insulin resistance value of 3.3 mg/dl, which is 
higher than usual.  
In general, diagnostic workup of adrenal incidentalomas aimed at the 
detection of malignancy or subclinical hormone excess. Therefore, many authors 
recommend an array of hormonal assays to search for any hormonal abnormality.  
Subclinical Cushing syndrome (SCS) is the most prevalent hormonal 
abnormality, found at a rate of 5-8% in patients with incidentalomas. Since impaired 
cortisol secretion with dexamethasone is an earlier sign, the low dose 
dexamethasone suppression test (ODST) is considered as the screening test in SCS 
(Babińska et al., 2012). As well as SCS, overt Cushing syndrome is ruled out in 
patients with a cortisol value of <1.8 μg/dl (50 nmol/l) after the ODST (Babińska et 
al., 2012).  
In our series, the median post ODST cortisol was 1.2 μg/dl, and most of the 
patients had a value of <1.8 μg/dl. Most probably, this is related to the mass size: 
Our series had median adrenal nodule diameters of 2.1 cm (longer nodule diameter) 
and 1,5 cm (shorter nodule diameter).  
It has been suggested that tumors of >3 cm are more likely to develop 
hyperfunction than smaller tumors (Muscogiuri et al., 2011; Morelli et al., 2014; 
Yılmaz et al., 2009).  
We could not find any correlation between adrenal mass size and cortisol 
secretion after1 mg dexamethasone suppression test. But, we found a correlation 
between longer adrenal nodule diameter and 24h urinary metanephrine levels. As for 
shorter adrenal nodule diameter, it has a significant negative correlation with renin.  
The positive correlation of adrenal mass size with metanephrine suggests that 
incidentaloma investigations should include analysis of plasma free metanephrines 
or urinary fractionated metanephrines, especially from the point of diagnosis of 
phaeochromocytomas and paragangliomas (van Berkel et al., 2014).  
Recent studies have shown that a high percentage of adrenal incidentalomas can be 
subclinically functioning, causing symptoms milder than those encountered in the 
well known adrenal hyperfunctioning symptoms (Linos, 2003).  
The fear of adrenal carcinoma, which has dictated the investigation of 
incidentalomas in the past, should leave its place to the dismay of mental function of 
these usually benign adrenal incidentalomas with coexisting metabolic pathology 
(Linos, 2003). 
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CONCLUSION  
We found that the relationship between adrenal mass size and 1 mg 
dexamethasone suppression test results was not statistically significant. Shorter 
nodule diameter was statistically significant in women, and also it is negatively 
correlated with serum renin levels. Longer adrenal nodule diameter was significantly 
correlated only with 24h urinary metanephrine levels. 
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